Complete If Known Application Number IST OF PATENTS AND 10/667,200 Filing Date August 18, 2003 NT'S INFORMATION First Named Inventor Kerstin KUHN-WACHE URE STATEMENT Art Unit 1614 as many sheets as necessary) Examiner Name Not Known Attorney Docket No. PBD-00027 (formerly 20488/57)

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION OR ISSUE DATE	INVENTOR	CLASS/ SUBCLASS
					
					

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION DATE	APPLICANT	COUNTRY	
			 			
		,	 			

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)
A	CCE	Lambeir A-M et al, (2001) FEBS Letters, 507 327-330.
A.	CCF	Engel M et al, (2003) PNAS, April 29, Vol 100(9) 5063-1068.
E	CCG	Kuehn-Wache K et al, Advances in Experimental Medicine and Biology, 2003, Vol. 524, p57-63, Springer, & International Conference on Dipeptidylaminopeptidases, Berlin, Germany, Sept 26-28, 2002.

EXAMINER States	Date Considered: 12/27/05

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFO	FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 20488/57		ERIAL NO 10/667,200	
•				APPLICANT(S): Kühn-Wache et	 al.		
-				FILING DATE: ART UNIT: September 18, 2003 Not Yet Assigned			ied
			UNITED STATE	S PATENT DOCUMENTS			
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
R	AA	2,961,377	11/22/1960	Shapiro et al.	167	65	
R	AB	3,174,901	03/23/1965	Sterne	167	65	
Я	AC	3,879,541	04/22/1975	Kabbe et al.	424	326	
R	AD	3,960,949	06/01/1976	Ahrens et al.	260	564 B	
8	AE	4,028,402	06/07/1977	Fischer et al.	260	501.14	
1	AF	4,935,493	06/19/1990	Bachovchin et al.	530	331	
8	AG	5,433,955	07/18/1995	Bredehorst et al.	424	94.3	
8	АН	5,462,928	10/31/1995	Bachovchin et al.	514	19	
3	ΑI	5,512,549	04/30/1996	Chen et al.	514	12	
R	AJ	5,543,396	08/06/1996	Powers et al.	514	19	
B	AK	5,614,379	03/25/1997	MacKellar	435	68.1	
S	AL	5,624,894	04/29/1997	Bodor	514	2	
8	AM	5,939,560	08/17/1999	Jenkins et al.	548	535	
8	AN	6,006,753	12/28/1999	Efendic	128	898	
g	AO	5,827,898	10/27/1998	Khandwala et al.	514	734	
8	AP	6,201,132 B1	03/13/2001	Jenkins et al.	548	535	04/21/99
S	AQ	6,303,661 B1	10/16/2001	Demuth et al.	514	866	04/24/97
8	AR	6,500,804 B2	12/31/2002	Demuth et al.	514	19	12/31/02
R	AS	6,319,893 B1	11/20/2001	Demuth et al.	514	2	11/20/01
8	AT	6,011,155	01/04/2000	Villhauer	544	333	
4	AU	6,107,317	08/22/2000	Villhauer	514	365	
8	AV	6,110,949	08/29/2000	Villhauer	514	365	
e	AW	6,124,305	09/26/2000	Villhauer	514	272	
4	AX	6,172,081	01/09/2001	Damon	514	307	
Examiner:		Asah 1	9	Date: /2/	27/4	<u> </u>	

		<i>\$</i> /					
INF	FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 20488/57	1	ERIAL NO. 10/667,200	
-			•	APPLICANT(S): Kühn-Wache et	al.		
				FILING DATE: September 18, 2003		RT UNIT: Yet Assign	ed
			UNITED STATE	S PATENT DOCUMENTS		,	
8	AY	5,705,483	01/06/1998	Galloway et al.	514	12	
7	AZ	2001/0025023 A1	09/27/2001	Carr	514	2	
8	AAA	6,548,481 B1	04/15/2003	Demuth et al.	514	19	11/28/00
-			FOREIGN P	ATENT DOCUMENTS	-		
4		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
L	ВА	WO 01/62266 A2 🗸	08/30/2001	PCT	A61K	38/00	Y
<	ВВ	WO 00/53171 🐓	09/14/2000	PCT	A61K	31/155	Y
8	вс	DT 25 42 598 A1	04/22/1976	Germany	C07C	129/16	N
۷	BD	FR 2 696 740 A1 🖊	04/15/1994	France	C07D	207/404	N
5	BE	FR 2 085 665 /	12/31/1971	France	A61K	27/00	N
8	BF	WO 97/40832/	11/06/1997	PCT	A61K	31/425	Abstract only
R	BG	WO 95/15309 <	06/08/1995	PCT	C07D	207/16	Y
8	вн	JP 4334357 🦟	11/20/1992	Japan	C07C	233/57	Abstract only
ß	BI	WO 93/08259 🖍	04/29/1993	PCT	C12N		Y
L	ВЈ	WO 95/11689 🗸	05/04/1995	PCT	A61K	37/00	Y
8	BK	WO 97/45117 🗸	12/04/1997	PCT	A61K	31/435	Y
Ŗ	BL	DE 196 16 486 C2 <	10/30/1997	Germany	A61K	45/00	Y
R	BM	WO 95/29691	11/09/1995	PCT	A61K	38/00	Y
l	BN	WO 98/22494	05/28/1998	PCT	C07K	5/06	Y
Я	во	WO 00/01849	01/13/2000	PCT	C12Q	1/68	Y
8	BP	EP 0 658 568 A1	06/21/1995	EPO	C07K	14/605	Y
8	BQ	DD 296 075 A5	11/21/1991	Germany	C07D	295/04	Y
P	BR	DD 296 075 A5	11/21/1991	Germany	C07D	295/04	N
<	BS	EP 0 708 179 A2	04/24/1996	EPO	C12N	15/16	Y
Examiner	•	Asal 18		Date: 17/29-1	18		

	FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20488/57		ERIAL NO. 10/667,200			
				APPLICANT(S): Kühn-Wache et	al.	·		
				FILING DATE: September 18, 2003		ART UNIT: Not Yet Assigned		
			FOREIGN P	ATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N	
	BT	EP-0-995-440-A1	04/26/2000	EPO	A61K	31/425	— N	
	BU	WO-91/11457	08/08/1991	PCT	C07K	7/34	Y	
	BV	WO-91/16339	10/31/1991	PCT	C07K	5/10	Y	
	BW	WO 98/19998	05/14/1998	PCT	C07D	207/00	Y	
	BX	WO 91/17767	11/28/1991	PCT	A61K	37/54	Y	
	ВҮ		10/13/1992	ЛР	A61K	37/64	(Abstract —Only)	
	BZ-	WO-99/46272-A	09/16/1999	PCT	C07F	9/572	Y	
	BAA	DE-299-09-210-U	09/09/1999	Germany	A61K	31/425	N	
	BAB	DE-198-26-972-A1	12/23/1999	Germany	A61K	38/05	N	
1	BAC	WO 01/97808	12/27/2001	PCT	A61K	31/425	Y	
	BAD-	WO 01/34594 A1	05/17/2001	PCT	C07D	_401/06_	Y	
8	BAE	WO 00/10549	03/02/2000	PCT	A61K	31/00	Y	
	-BAF-	WO-01/74299-A2	10/1-1/2001	PCT	A61K		. Y	
	-BAG-	WO 02/20825 A1	03/14/2002	PCT	C12Q	1/00	Y	
	ВАН	WO-01/89569-A-1	11/29/2001	PCT	A61K	45/06	— Y	
	-BAI	WO 99/62914	12/09/1999	PCT	C07F	5/02	Y	
	BAJ	WO 99/61431	12/02/-1999	PCT	C07D	277/04	Abstract Only-	
	-BAK-	EP 1 130 022 A1	09/15/2001	ЕРО	C07D	498/09	Y	
	BAL	WO 01/32624 A1	05/10/2001	PCT	C07D	217/04	Y	
	BAM	WO-01/09169 A2	02/08/2001	PCT	C07K	5/062	Υ	
	BAN	WO 01/94310 AT	12/13/2001	PCT	C07D	209/12	Y	
Examine	er:	SSal-		Date: /2/2	210	·		

13	& /					
INFORM	FORM PTO-1449 ATION DISCLOSURE STATEMENT		OCKET NO. 188/57	SERIAL NO. 10/667,200		
		APPLICANT(S)	: Kühn-Wache et al			
	·		G DATE: per 18, 2003	ART UNIT: Not Yet Assigned		
	OTHER DOCUMENTS (INCLUDING AU	THOR, TITLE,	DATE, PERTINEN	T PAGES, ETC.)		
& CA	Campbell, I.W. New Antidiabetic Drugs, ed. efficacy and inadequacy". 3:33-51 (1990).	C.J. Bailey & P.R	. Flatt, Smith-Gordon	, "Sulphonylureas and metformin:		
СВ	149947q, SCHOEN-EKKEHARD-ET-AL: "D	CHEMICAL ABSTRACTS, vol. 115. No. 15, 14. October 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN-EKKEHARD-ET-AL: "Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes"				
CC	CHEMICAL ABSTRACTS, vol. 118, no. 25, Hosoda, et-al, "Preparation of N-(heterocyclic November 1992 (1992-11-20)	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21. June 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Hosoda, et al, "Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors", November 1992 (1992-11-20)				
CD	CHEMICAL ABSTRACTS, vol. 126, no. 2, 1 STOECKEL A. ET AL: "Competitive inhibiti thiazolidides".	CHEMICAL ABSTRACTS, vol. 126, no. 2, 13. January 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL-AET-AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides".				
·——CE—	Martindale-The Extra-Pharmacopoeia, 30th Edition, London Pharmaceutical Press, 1993, Page 1619.					
L CF	AMASHEH, S., et al., "Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes". J. Physiol. 504, 169-174 (1997)					
CG	Arai ET AL., "Synthesis of prolyl endopeptid vitro inhibition of prolyl endopeptidase from 41, No. 9, 1993, pages. 1583-1588.	ase inhibitors and Canine Brain" <u>CH</u>	evaluation of their str EMICAL AND PHA	ructure-activity relationships: in RMACEUTICAL BULLETIN., Bd.		
СН	DURINX, C.; et al.; "Reference Values for P Laboratory Parameters". Clin Chem Lab Me					
·CI	GOSSRAU, R.; "Cytochemistry of Membrane	e Proteases". Hist	ochem J. 1985, July:	17 (7):737-71, 1 page.		
Cı	HAHN, T.; et al.; "Enzyme Histochemical Ev Cultured Villous Explants from Human First" page.	ridence for the Pre Trimester Placenta	sence of Potential Blo ne". Acta Histochem	nod Pressure Regulating Proteases in 1993, December, 95 (2):185-92, 1		
& CK	HEYMANN, E. et al., "Has Dipeptidyl Peptid 1984, January, 2;62 (1):2-10, 1 page.	dase IV an Effect of	on Blood Pressure and	d Coagulation." Klin Wochenschr,		
CL	Lin, J. et al.: "Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, Vol. 95, November 1998, pages 14020-14024.					
CM	KOROM, S., et al "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients", <u>Transplantation</u> , Vol. 63, 1495 – 1500 No. 10 (1997)					
CN	MAGYAR, C.E. et al., "Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension." Am J. Physiol Renal Physiol, 2000, August; 279 (2):F358-69, 1 page.					
CO-	Martindale The Extra Pharmacopoeia, 30th Ec	lition, London Ph	armaceutical Press, 19	993, Page 36.		
Examiner:	Scatz		Date: 12/27/4	f		

IN	POLENIA.	FORM PTO-1449 ATION DISCLOSURE STATEMENT	l	OCKET NO. 488/57	SERIAL NO. 10/667,200	
•			APPLICANT(S)	: Kühn-Wache et	al.	
				G DATE: per 18, 2003	ART UNIT: Not Yet Assigned	
		OTHER DOCUMENTS (INCLUDING AU	THOR, TITLE,	DATE, PERTINE	NT PAGES, ETC.)	
	СР	MENTLEIN, R., et al., "Proteolytic processin Pept. 49, 133 -144 (1993)	g of neuropeptide	Y and peptide YY	by dipeptidyl peptidase IV". Regul.	
	CQ	PAPIES, B. et al., "Isoenzyme (Lactate Dehydrogenase, Aspartate-Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension." Cor Vasa, 1991; 33 (3):218-26, 1 page.				
	CR	URESHI. N.U.; et al., "Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic hock". Regul Pept, 1998, September 25; 75-76:215-20, 1 page.				
	CS —	TANKA, S., et al., "Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV". Int. J. Immunopharmacol, V 19, No. 1 Pages 15-24, (1997)				
	CT	The Merck Index, 11th Edition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1989, Page 934				
	СŲ	The Merck-Index, 12th Edition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, Page 1014.				
ξ.	CV	Deacon et al., <u>Journal of Clinical Endocrinology and Metabolism</u> , "Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields and N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo", (1995), 80(3): 952-957.				
R	CW	G.G. Duncan, Diseases of Metabolism (Asian	edition), "Diabet	es Mellitus", (1966)), p 951-957.	
	CX	Gutniak-et al., <u>Diabetes Care</u> , "Subcutaneous Postprandial Glycemia in NIDDM", Septemb			ucagon-Like Peptide 1 Abolishes	
	CY	Gutniak et al., New England Journal of Medi Normal Subjects and Patients With Diabetes			ncagon-like peptide-1 (7-36) Amide in	
	CZ	H.A. Smith et al., Veterinary Pathology (four (1972), p 1018-1020.	th edition), "Disea	ses and Disorders c	of Metabolism: Deficiency Diseases",	
	CAA	Hendrick et al., Metabolism – Clinical and Ex Rats", January 1993, 42(1): 1-6.	eperimental, "Glue	cagon-like Peptide-l	(-(7-37) Suppresses Hyperglycemia in	
	CAB	Hoffmann et al., <u>Journal of Chromatography A</u> , "Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro-oligopeptides ascertained by capillary eletrophoresis", 1995, 716:355-362.				
,	CAC	Index Nominum, International Drug Directory 1992/1993, Medpharm Scientific Publishers, pages 728-729.				
	CAD	Mannucci et al., Diabetes Care, "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects", 24(3): 489-494, March 2001.				
	CAE	Nauck et al., Diabetologia, "Normalization of in Type 2 (non-insulin-dependent) diabetic pa	f fasting hyperglyontients", (1993), 3	eaemia by exogenou 6: 741-744.	ns glucagon-like peptide 1 (7-36 amide	
	CAF	Pauly et al., Regulatory Peptides, "Abstracts Issue: Abstracts from the 11 th International Symposium on Regulatory Peptides,", July 15, 1996, 64(1-3): 148 plus cover.				
Examin	er:	Asah 18		Date: R/29	18	

INFORM	FORM PTO-1449 ATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 20488/57	SERIAL NO. 10/667,200			
	•	APPLICANT(S): Kühn-Wache	et al.			
•		FILING DATE: September 18, 2003	ART UNIT: Not Yet Assigned			
	OTHER DOCUMENTS (INCLUDING AU	THOR, TITLE, DATE, PERTIN	ENT PAGES, ETC.)			
CAG	Stryer, Biochemistry 3rd Ed., "Protein Conformation of the Biochemistry 3rd Ed.,"	nation, Dynamics, and Function", 1	988, p 191-193.			
САН	T.J. Kieffer et al., "Degradation of Glucose-D In Vitro and In Vivo by DP IV", Endocrinolog					
CAI	The Merck Index, An Encyclopedia of Chemi	cals and Drugs, 9th Edition, Merck	& Co., Inc., 1976, page 773			
CAJ	C.B. Welch, Medical Management of Non-Installation, "Diagnosis and Classification" p					
CAK	WETZEL, W., et al., "Effects of the CLIP fra Neuropeptides, 31, 41- 45 (1997)	gment ACTH 20-24 on the duration	of REM sleep episodes".			
CAL	Willms et al., <u>Journal of Clinical Endocrinology Metabolism</u> , "Gastrie Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients", 1996, 81(1): 327-332.					
CAM	Ashworth et al., BIOORG, MED. CHEM. LETT., "2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", (1996), 6(10): 1163-1166.					
CAN	Badia-Elder N.E. et al., Alcoholism-Clinical and Experimental Research, "Effects of Neuropeptide Y (NPY) on Ethanol Intake and Anxiety in High and Low Alcohol Drinking (HAD1/LAD1) Rats", (2000), 24(5): 82A.					
& CAO		C.F. Deacon et al., <u>Diabetes</u> , "Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded from the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects", September 1995, 44: 1126-1131.				
CAP	Edwards, J.V. et al., J. Peptide Res., "Synthes Sequences on Cotton," (1999), 54: 536-543.	is and Activity of NH ₂ - and COOH	I-Terminal Elastase Recognition			
CAQ	Endroczi et al., <u>ACTA PHYSIOL. HUNG.</u> , "I Thymus-Derived Lymphocytes: Effects of Inh	Dipeptidyl peptidase IV (DP IV) and ibitory Pepdides and Zn2+ in Vitro'	d Superoxide Dismutase Activity in (1990), 75(1): 35-44.			
CAR	Frohman et al., <u>Journal of Clin. Invest.</u> , "Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma in Vitro and in Vivo to a Biologically Inactive Product Cleaved at the NH ₂ Terminus", Volume 78, October 1986, p 906-913					
-CAS-	Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), p. 1510.					
CAT	Hyun Sook Lee et al., "Cathepsin B Inhibitory Peptides Derived from β-Casein," Peptides 21 (2000) 807-809.					
CAU	Nathan et al., Diabetes Care, "Insulinotropic J Subjects", February 1992, 15(2): 270-275.	Nathan et al., Diabetes Care, "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects", February 1992, 15(2): 270-275.				
CAV		Pauly et al., Metabolism, "Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-Thiazolidide", (1999), 48(3): 385-389.				
CAW	Pschyrembel, Kininisches Wörterbuch 257, A	uflage, (1994), 9 pages.				
Examiner:	Alaky	Date: 12/74	105			

•		FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. SERIAL NO. 10/667,200			
•			APPLICANT(S)	: Kühn-Wache	e et al.		
			1	G DATE: per 18, 2003	ART UNIT: Not Yet Assigned		
		OTHER DOCUMENTS (INCLUDING AU	THOR, TITLE,	DATE, PERTI	NENT PAGES, ETC.)		
	CAX	Snow et al., Advances In Medicinal Chemistry Immunosuppressive Agents", Vol. 3, (1995), p		Inhibitors of Dip	peptidyl Peptidase IV: A New Class of		
Se.	CAY	Thorens et al., <u>Diabetes</u> , "Glucagon-Like Pepe NIDDM", (1993), 42:1219-1225.	tide-I and the Co	ntrol of Insulin S	Secretion in the Normal State and in		
	CAZ_	Vidal, (1993), 69th Edition, p. 612-613.					
	СВА	Wakselman et al., "Inhibition of HIV-1 infection of PP IV activity of CD26", Abstract P 44 of the	on of CD 26 ⁺ but e 24 th <u>European F</u>	not CD 26 cells eptide Symposi	by a potent cyclopeptidic inhibitor of the um, (1996).		
	СВВ	Wettstein, J.G. et al. <u>Pharmacology & Therape</u> (1995),-65(3):-397-414.	eutics, "Central N	ervous System P	Pharmacology of Neuropeptide Y.",		
-	CBC	Bergmeier, Stephen C., <u>Tetrahedron</u> , <u>Elsevier</u> (2000), pages 2561-2576.	Bergmeier, Stephen C., <u>Tetrahedron, Elsevier Science Ltd.</u> , "The Synthesis of Vicinal Amino Alcohols", Vol. 56, No. 17 (2000), pages 2561-2576.				
	CBD	Kowamoto et al., <u>Tetrahedron Asymmetry</u> , <u>Elsevier Science Ltd.</u> , "Enantioselective Synthesis of β-Hydroxy Amines and Aziridines Using Asymmetric Transfer Hydrogenation of α-Amido Ketones", Vol. 11, No. 16 (2000), pages 3257-3261.					
	CBE	Munglani R. et al., Drugs, Adis International Ltd, At, "The Therapeutic Potential of Neuropeptide Y Analgesic, Anxiolytic and Antihypertensive", (1996) 52(3): 371-389.					
	CBF	Orskov, Cathrine et al., "Proglucagon Products in the Fasting State and after Oral Glucose and					
	CBG	Reinhold, D. et al., <u>Journal of Neuroimmunology</u> , " <u>Inhibitors of Dipeptidyl Peptidase IV</u> /CD26 Suppress Activation of Human MBP-Specific CD4 + T Cell Clones", (1998) 87: 203-209.					
	СВН	Sengupta, et al., <u>Tetrahedron Letters, Elsevier Science Ltd.</u> "Amino Acid Derived Morpholine Amides for Nucleophilic α-Amino Acylation Reactions: A New Synthetic Route to Enantlopure α-Amino Ketones", Vol. 40, No. 21 (1999), pages 4107-4110.					
	CBI	Stöckel-Maschek, A., et al., Biochimica et Biophysica Acta, "Thioxo Amino Acid Pyrrolidides and Thiazolidides: new Inhibitors of Proline Specific Peptidases", (2000) 1479: 15-31.					
	CBJ	Stryer, Lubert, Biochemistry, "Amino Acid De	egradation and the	Urea Cycle" (1	1975) pages 451-452.		
E	СВК	Mentlein et al., <u>Eur. J. Biochem</u> , Dipeptidyl-Peptidase IV Hydrolyses Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)Amide, Peptide Histidine Methionine and is Responsible for Their Degradation in Human Serum. (1993), 214, pages 829-835.					
1	CBL	Augustyns et al., Eur. J. Med. Chem., "Pyrroli Dipeptidyl Peptidase IV", (1997), vol. 32, pag		and Structure-Ac	ctivity Relationship as Inhibitors of		
	СВМ	Wen-Tien Chen et al. "Seprase Complexes in (2003).	Cellular Invasive	ness", <u>Cançer an</u>	nd Metastasis Reviews 22: 259-269,		
Examine		h. I= P		Date: 12/	27/8		

FORM PTO-1449 ATTY. DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE STATEMENT 10/667,200 20488/57 APPLICANT(S): Kühn-Wache et al. FILING DATE: ART UNIT: September 18, 2003 Not Yet Assigned OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) **CBN** Victor A. Gault et al., "Glucose-Dependent Insulinotropic Polypeptide Analogues and Their Therapeutic Potential for the Treatment of Obesity-Diabetes", Biochemical and Biophysical Research Communications 308: 207-213, (2003). CBO Lader, Malcolm-H., MD, "Assessment Methods and the Different Diagnosis of Anxiety", Journal of Clinical Psychopharmacology, (1981), Vol. 1, No. 6, pp. 342-349. **CBP** Winslow, R., "Novartis Drug Alters Picture for Diabetes" Wall Street Journal, Wed., December 27, 2000, p. B2. CBQ Ansorge, S., et al., "Membrane-bound peptidases of lymphocytes: Functional implications", Biomed. Biochim, Acta 50 (1991) 4-6, pp. 799-807. **CBR** Dodge, R.W., et al., "Folding and Unfolding Kinetics of the Proline-to-Alanine Mutants of Bovine Pancreatic Ribonuclease A," Biochemistry 1996, 35, pp. 1548-1559. Hans-Ulrich Demuth, "Recent Developments in Inhibiting Cysteine and Serine Proteases", J. Enzyme Inhibition, 1990, **CBS** Vol. 3, pp. 249-278. CBT Gomez, S., et al., "Relationship between endo- and exopeptidases in a processing enzyme system: Activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase", Proc. Natl. Acad. Sci. USA, Vol. 85 pp. 5468-5472, August 1988. Hegen, M., et al., "The T Cell Triggering Molecule Tp103 is Associated with Dipeptidyl Aminopeptidase IV Activity," CBU The Journal of Immunology, vol. 144, pp. 2908-2914, No. 8, April 15, 1990. CBV Ishiura, S., et al., "Identification of a putative-amyloid A4-generating enzyme as a prolyl endopeptidase," Federation of European Biochemical Societies, Vol. 260, No. 1, pp. 131-134, January 1990. Kräusslich, Hans-Georg, et al., "Viral Proteinases", Ann. Rev. Biochem. 1988, 57 pp. 701-754. CBW Pederson, R.A., et al., "Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl CBX Peptidase IV Inhibitor Isoleucine Thiazolidide", Diabetes, Vol. 47, August 1998 pp. 1253-1258. **CBY** Vanhoof, G., et al., "Proline motifs in peptides and their biological processing", The FASEB Journal, Vol. 9, June 1995, pp. 736-744. Walter, R., et al., "Proline Specific Endo- and Exopeptidases", Molecular & Cellular Biochemistry, Vol. 30, No. 2, April CBZ 18, 1980, pp. 111-127 **CBA** Kessler, Von Horst, "Konformation und biologische Wirkung von cyclischen Peptiden", Angew Chem. 94 (1982) pp. 509-520. Kirschke, H. et al., "Proteinases 1: Lysosomal Cysteine Proteinases" Protein Profile, Vol. 2, Issue 14, 1995, pp. 1583-CCB-1634. Yaron, A., et al., "Proline-Dependent Structural and Biological Properties of Peptides and Proteins" Critical Reviews in Biochemistry and Molecular Biology, 28(1), pp. 31-81 (1993). CCD Vallee et al., "Larval Development of Tribolium Confusum in the Presence of Non-Naturally Occurring Amino Acids", Database CAPLUS on STN, Accession No.: 1963:75103, Annales de l'ACFAS (1962), 28, p. 26-27 (abstract). Date: Examiner: